Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Adenocarcinoma of the Prostate Clinical Trial

Official title:

Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02023463
• Other study ID #: 13P.461
• Secondary ID: 2013-027
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: April 2, 2014
• Est. completion date: January 1, 2040

Study information

• Verified date: October 2023
• Source: Thomas Jefferson University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best way to give enzalutamide, radiation therapy, and hormone therapy in treating patients with intermediate or high-risk prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. Giving enzalutamide, radiation therapy, and hormone therapy may be an effective treatment for prostate cancer.

Description:

PRIMARY OBJECTIVE:

1) To assess the safety of the combination of neoadjuvant and concurrent enzalutamide with an luteinizing-hormone-releasing hormone (LHRH) agonist and radiation therapy.

SECONDARY OBJECTIVES:

1. To determine the efficacy of the combination of enzalutamide with an LHRH agonist and radiation therapy using prostate specific antigen (PSA) kinetics.

2. To determine the efficacy of the combination of enzalutamide with an LHRH agonist and radiation therapy using PSA nadir.

3. To describe patient-reported outcomes including: Expanded Prostate Cancer Index Composite (EPIC), American Urological Association (AUA) Symptom Index, PROstate magnetic resonance (MR) Imaging Study (PROMIS) Fatigue Scale.

OUTLINE:

Patients receive enzalutamide orally (PO) once daily (QD) for 6 months. Beginning 2 weeks after start of enzalutamide, patients receive LHRH agonist therapy with goserelin acetate subcutaneously (SC) or leuprolide acetate intramuscularly (IM) or SC for 6 months (intermediate risk patients) or 24 months (high risk patients) post-radiation therapy. Beginning 8 weeks after the start of LHRH agonist therapy, patients undergo either intensity modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) daily five days a week for 8 weeks.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: January 1, 2040
• Est. primary completion date: July 10, 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Prostate adenocarcinoma without distant metastatic disease with either Gleason score = 7, PSA = 10 ng/ml, or T2b or greater disease

2. Age > 18

3. Performance Status: ECOG 0-1

4. Hematologic (minimal values):

• Absolute neutrophil count > 1,500/mm3

• Hemoglobin > 8.0 g/dl

• Platelet count > 100,000/mm3

5. Hepatic function

• Total bilirubin < Upper limit of normal (ULN)(except for Gilbert's disease)

• AST (SGOT) < 1.5 x ULN

• ALT (SGPT) < 1.5 x ULN

6. Creatinine < 1.5 x ULN

7. Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.

Exclusion Criteria:

1. Patients with a history of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, brain arteriovenous malformation or the use of concomitant medications that may lower the seizure threshold

2. History of urological surgery or procedures predisposing to GU complications after radiation (will be determined by radiation oncologist)

3. History of diverticulitis, rectal bleeding or other lower GI diseases predisposing to GI complications after radiation (will be determined by radiation oncologist)

4. History of prior chemotherapy or pelvic irradiation,

5. History of prior invasive malignant cancer(s) within the last 5 years except adequately treated or controlled basal cell or squamous cell carcinoma of the skin.

6. Documented distant metastatic disease. NOTE: pelvic lymphadenopathy is NOT excluded.

7. Prior radical prostatectomy or cryosurgery for prostate cancer or bilateral orchiectomy.

8. No experimental medications within 30 days of study entry

9. Patients currently taking the following medications:

• CYP2C8 inhibitors (e.g. Gemfibrozil)

• CYP2C8 inducers (e.g. rifampin)

• CYP3A4 inhibitors (itraconazole)

• CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine)

Related Conditions & MeSH terms

• Adenocarcinoma of the Prostate
• Prostatic Neoplasms
• Recurrent Prostate Cancer
• Stage IIB Prostate Cancer
• Stage III Prostate Cancer
• Stage IV Prostate Cancer

Intervention

Drug:
• Enzalutamide
Given PO
• Goserelin acetate
Given SC
• Leuprolide acetate
Given IM or SC

Radiation:
• Radiation therapy
Undergo image-guided radiation therapy

Locations

Country	Name	City	State
United States	Thomas Jefferson University	Philadelphia	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Sidney Kimmel Cancer Center at Thomas Jefferson University	Astellas Pharma Inc, Medivation, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acute toxicities, monitored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 criteria	An exact 2-sided binomial 90% confidence interval will be computed and reported. Toxicity will be monitored and if there is greater than 10% incidence of grade 3 or higher gastrointestinal (GI)/genitourinary (GU)/fatigue lasting more than 7 days despite optimal treatment, the trial will be re-evaluated.	Up to 1 month post completion of enzalutamide
Secondary	Change in PSA levels	Evaluated using linear mixed models. Mixed models will make use of all available data, and can estimate individual levels of change.	Baseline up to 6 months
Secondary	Quality of life (QoL), measured using the EPIC, AUA symptom index, and the PROMIS Fatigue Scale	QoL measures will also be assessed via linear mixed models, as an exploratory evaluation of potential clinical correlates, such as age, race, stage, Gleason score, etc.	Baseline up to 1 year

External Links

•   Thomas Jefferson University Hospitals